Research Paper Volume 14, Issue 13 pp 5493—5510

Figure 1. The expression of RBX1 was over-expressed in the metastatic TNBC and greatly related to poor outcomes of patients. (A) Expression of RBX1 mRNA in the dataset of TCGA TNBC cancer. (B) Correlation with the clinicopathological features and expression of RBX1 in patients with TNBC in TCGA cohort. (C, D) qRT-PCR was utilizing for analysing RBX1 mRNA expression levels in the tissues of TNBC tissues as well as their adjoining non-carcinoma normal tissues. ^*P<0.05, ^**P<0.01. (E, F) Western blotting was applying for studying RBX1 protein expression levels in the tissues of TNBC tissues together with their adjoining non-carcinoma normal tissues. ^**P<0.01. (G) Immunohistochemistry was employed to identify The RBX1 protein expression existing in the tissues of TNBC and their neighboring non-carcinoma normal tissues. Scale bar, 50 μm. (H, I) For the overall survival (H) and the disease-free survival (I) in two groups of patients with TNBC, their Kaplan-Meier curves were defined by the low and high RBX1 expression, respectively. (J) In analysing the database of UALCAN, the expression of RBX1 was markedly elevated in metastatic and breast cancer tissues.